RESVERATROL AND ITS BENEFITS, MY PRESENTATION ON SLIDESHARE

Advertisements

Xarelto approved for Secondary prevention in Acute Coronary Syndrome patients in Europe

Ferring Presents Phase III Data for a Controlled Release Misoprostol Vaginal Delivery System for Labour Induction at the First European Congress on Intrapartum Care

New Drug Approvals

MISOPROSTOL

READ AT

http://www.nationalpost.com/markets/news/Ferring%2BPresents%2BPhase%2BData%2BControlled%2BRelease%2BMisoprostol%2BVaginal/8429878/story.html

Misoprostol is a synthetic prostaglandin E1 (PGE1) analog that is used for the prevention of nonsteroidal anti-inflammatory drug (NSAID) induced gastric ulcers, to treat missed miscarriage, to induce labor, and as an abortifacient. The latter use is controversial in theUnited States. Misoprostol was invented and marketed by G.D. Searle & Company (nowPfizer) under the trade name Cytotec, but other brand-name and generic formulations are now available as well.

Misoprostol is approved for use in the prevention of NSAID induced gastric ulcers. It acts upon gastric parietal cells, inhibiting the secretion of gastric acid via G-protein coupled receptor mediated inhibition of adenylate cyclase, which leads to decreased intracellularcyclic AMP levels and decreased proton pump activity at the apical surface of the parietal cell. Because

View original post

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

New Drug Approvals

preladenant

Merck , known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment of Parkinson’s disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo…..read more at

Links

http://www.businesswire.com/news/home/20130523006358/en/Merck-Update-Phase-III-Clinical-Program-Preladenant

Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson’s disease.Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013

View original post